Mitsubishi Tanabe Pharma Corporation (三菱田辺製薬株式会社, Mitsubishi Tanabe Seiyaku Kabushiki-gaisha) is a major Japanese pharmaceutical company headquartered in Osaka, Japan. The company is a subsidiary of Mitsubishi Chemical Holdings and is one of Japan's largest pharmaceutical companies, with a significant global presence in neurodegenerative disease therapeutics. Mitsubishi Tanabe has established itself as a leader in Parkinson's disease treatment through its flagship product Azilect (rasagiline), one of the most widely prescribed MAO-B inhibitors worldwide[@mitsubishi][@azilect].
The company's commitment to neuroscience research spans over a century, with roots dating back to the early Japanese pharmaceutical industry. Mitsubishi Tanabe has made substantial contributions to the treatment of neurological disorders, particularly Parkinson's disease, and continues to invest heavily in research for novel therapeutics targeting neurodegenerative conditions. The company's pipeline includes programs in Parkinson's disease, ALS, Alzheimer's disease, and other CNS disorders[@mitsubishi][@mitsubishia].
| Attribute |
Value |
| Company Name |
Mitsubishi Tanabe Pharma Corporation |
| Japanese Name |
三菱田辺製薬株式会社 |
| Stock Exchange |
Tokyo Stock Exchange (TSE: 4508) |
| Headquarters |
Osaka, Japan |
| Founded |
2007 (current corporate form) |
| Parent Company |
Mitsubishi Chemical Holdings Corporation |
| CEO |
Masayuki Mitsuka |
| Employees |
~6,500 |
| Revenue |
~¥500 billion (~$3.5 billion USD, 2024) |
| R&D Investment |
~¥80 billion annually |
| Website |
mt-pharma.co.jp |
Mitsubishi Tanabe Pharma's corporate history reflects the broader development of the Japanese pharmaceutical industry:
Tanabe Seiyaku (1912-2007)
- 1912: Founded as Tanabe Seiyaku by Chobei Tanabe in Osaka
- 1940s: Expanded into modern pharmaceutical manufacturing
- 1950s: Developed major prescription drug portfolio
- 1970s: Entered CNS drug development
- 2000s: Established global presence
Mitsubishi Tanabe (1925-2007)
- 1925: Established as Mitsubishi Tanabe Seiyaku
- Post-war: Rebuilt operations and expanded globally
- 1970s-80s: Developed CNS pipeline including Azilect precursor
- 1990s: Expanded into biotechnology
- 2007: Merger of Mitsubishi Tanabe Pharma and Yomeishu Seishu to form current company
- 2010s: Strengthened global partnerships and expansion
- 2020s: Focused on specialty pharmaceuticals and CNS pipeline
Mitsubishi Tanabe operates as part of Mitsubishi Chemical Holdings (MCHC), one of Japan's largest chemical companies:
- MCHC Portfolio: Pharmaceuticals, chemicals, advanced materials
- Synergies: Access to research resources and global networks
- Strategic direction: Focus on healthcare and specialty chemicals
Azilect (generic name: rasagiline) is Mitsubishi Tanabe's most successful pharmaceutical product and represents a cornerstone of Parkinson's disease therapy worldwide:
| Property |
Value |
| Generic Name |
Rasagiline mesylate |
| Brand Name |
Azilect |
| Mechanism |
Monoamine oxidase B (MAO-B) inhibition |
| Indication |
Parkinson's disease (initial and advanced) |
| Route |
Oral |
| Dosage |
1 mg once daily |
| FDA Approval |
May 2006 |
| EMA Approval |
2005 |
| Japanese Approval |
2005 |
Rasagiline exerts its therapeutic effects through irreversible inhibition of monoamine oxidase B (MAO-B), the enzyme responsible for metabolizing dopamine in the brain[@arias_2014][@maurier_2017]:
- MAO-B Inhibition: Irreversibly binds to and inhibits MAO-B enzyme
- Dopamine Preservation: Reduces breakdown of endogenous dopamine
- Dopaminergic Transmission: Enhances dopaminergic signaling in the striatum
- Symptom Control: Improves motor function in PD patients
Research has demonstrated additional neuroprotective effects of rasagiline beyond MAO-B inhibition[@youdim_2013][@chen_2017]:
- Anti-apoptotic effects: Activation of pro-survival signaling pathways (PKC, MAPK)
- Mitochondrial protection: Preservation of mitochondrial function
- Neurotrophic effects: Enhancement of GDNF and BDNF expression
- Anti-inflammatory actions: Reduction in microglial activation
- Synaptic protection: Preservation of dopaminergic nerve terminals
¶ Clinical Development and Approval
Rasagiline Clinical Trials
- TEMPO Study (Phase II): Initial efficacy in early PD patients
- ADAGIO Study (Phase III): Disease modification in early PD
- PRESTO Study (Phase III): Efficacy in advanced PD
- Japanese clinical trials: Registration studies for Japan approval
| Market |
Year |
Notes |
| Israel |
2004 |
First approval |
| European Union |
2005 |
Centralized procedure |
| United States |
2006 |
FDA approval |
| Japan |
2005 |
PMDA approval |
Rasagiline has demonstrated efficacy across multiple clinical trials[@barber_2013][@weinreb_2015]:
- Early PD: Significant improvement in UPDRS scores vs. placebo
- Advanced PD: Reduction in "off" time when added to levodopa
- Motor fluctuations: Decreased time to "on" with less dyskinesia
The ADAGIO study investigated rasagiline's disease-modifying potential[@oertel_2020][@jellinger_2016]:
- Primary endpoint: Change in UPDRS score from baseline
- Results: Suggestive of disease modification in early PD
- Interpretation: Remains debated in field, but preclinical data support neuroprotection
Azilect competes with other MAO-B inhibitors and Parkinson's disease therapies:
| Drug |
Company |
Mechanism |
Status |
| Azilect |
Mitsubishi Tanabe |
MAO-B inhibitor |
Approved |
| Eldepryl |
Somerset (generic) |
MAO-B inhibitor |
Approved |
| Xedrine |
generic |
MAO-B inhibitor |
Approved |
Mitsubishi Tanabe maintains a comprehensive Parkinson's disease treatment portfolio:
| Drug |
Type |
Mechanism |
Status |
| Azilect |
MAO-B inhibitor |
Dopamine preservation |
Approved |
| Reminyl |
Cholinesterase inhibitor |
Cognitive symptoms |
Approved (Japan) |
| Trileptal |
Anticonvulsant |
Motor complications |
Approved |
The company's active Parkinson's disease research programs include[@mitsubishi]:
| Drug |
Target |
Mechanism |
Stage |
| MT-8554 |
Disease modification |
Undisclosed |
Preclinical |
| MT-8566 |
Alpha-synuclein |
Aggregation inhibitor |
Discovery |
| MT-8577 |
Neuroinflammation |
Microglial modulation |
Discovery |
Mitsubishi Tanabe is pursuing several innovative therapeutic approaches:
- Alpha-synuclein aggregation inhibitors: Targeting protein aggregation pathology[@foltynie_2021]
- Neurotrophic factor enhancers: Promoting neuronal survival[@nagatsu_2014]
- Cell replacement therapies: Dopaminergic neuron transplantation[@bjorklund_2020]
- Disease-modifying antibodies: Immunotherapeutic approaches
Mitsubishi Tanabe has an active ALS (amyotrophic lateral sclerosis) research program:
| Drug |
Target |
Stage |
Mechanism |
| MT-7116 |
Undisclosed |
Preclinical |
Neuroprotection |
¶ ALS Therapeutic Landscape
The company contributes to the significant unmet need in ALS treatment:
| Current Therapy |
Company |
Mechanism |
| Riluzole |
Generic |
Glutamate modulation |
| Edaravone |
Mitsubishi Tanabe |
Free radical scavenging |
| Tofersen |
Biogen |
SOD1 gene therapy |
Mitsubishi Tanabe's Edaravone (Radicut/Radicava) represents a significant contribution to ALS therapy:
- Mechanism: Free radical scavenging, neuroprotection
- Approval: Japan (2015), USA (2017)
- Impact: First new ALS therapy in decades
Mitsubishi Tanabe maintains Alzheimer's disease research programs despite the challenging therapeutic landscape:
| Area |
Approach |
Status |
| Amyloid-beta targeting |
Antibody therapy |
Discovery |
| Tau protein modulation |
Phosphorylation inhibitors |
Discovery |
| Neuroinflammation |
Microglial modulators |
Discovery |
| Synaptic protection |
Neurotrophic enhancement |
Discovery |
The company pursues Alzheimer's research through:
- Academic partnerships with Japanese universities
- International collaborations with global pharmaceutical companies
- Government-funded research consortia
Mitsubishi Tanabe has defined core therapeutic areas:
| Priority Area |
Key Products |
Pipeline Programs |
| Neurology/Psychiatry |
Azilect, Edaravone |
PD, ALS, AD |
| Immunology |
Various |
Autoimmune disorders |
| Rare Diseases |
Enzyme therapies |
Lysosomal storage |
The company is expanding its global presence:
- United States: Established sales and marketing presence
- Europe: European Medicines Agency approvals
- Asia-Pacific: Regional partnerships and expansion
- Emerging markets: Generic and branded product launches
Mitsubishi Tanabe commits substantial resources to R&D:
- Annual R&D spending: ~¥80 billion ($550 million USD)
- R&D as % revenue: ~16%
- Clinical programs: 20+ active programs
- Research sites: Japan, US, Europe
¶ Clinical Evidence and Publications
Mitsubishi Tanabe'sAzilect has been validated in extensive clinical research:
- TEMPO Study — Established efficacy in early Parkinson's disease
- ADAGIO Study — Investigated disease modification
- PRESTO Study — Demonstrated efficacy in advanced disease
- Multiple open-label extensions — Long-term safety and efficacy
| Study |
Phase |
N |
Duration |
Key Finding |
| TEMPO |
II |
404 |
26 weeks |
Significant UPDRS improvement |
| ADAGIO |
III |
1,176 |
72 weeks |
Suggestive of disease modification |
| PRESTO |
III |
687 |
18 weeks |
Reduced "off" time |
¶ Competitive Landscape
| Company |
CNS Focus |
Key Products |
| Takeda |
GI, CNS |
Trintellix |
| Astellas |
Oncology, CNS |
Various |
| Daiichi Sankyo |
Cardiovascular |
CNS pipeline |
| Eisai |
Neurology |
Aricept, Leqembi |
Mitsubishi Tanabe competes globally:
| Company |
Key PD Products |
Market Share |
| AbbVie |
Duodopa, Duopa |
Significant |
| GSK |
Requip, Azilect (EU) |
Moderate |
| Novartis |
Stalevo |
Moderate |
| Mitsubishi Tanabe |
Azilect |
Significant |
¶ Manufacturing and Quality
Mitsubishi Tanabe maintains manufacturing capabilities:
- Osaka headquarters: API and formulation manufacturing
- Japanese plants: Multiple GMP facilities
- Quality systems: Japanese Pharmaceutical and Medical Devices Agency (PMDA) compliant
¶ Global Quality Standards
- Japan: PMDA manufacturing approval
- USA: FDA cGMP compliance
- Europe: EMA GMP certification
¶ Sustainability and Corporate Responsibility
Mitsubishi Tanabe participates in broader Mitsubishi Chemical Holdings sustainability programs:
- Carbon neutrality goals
- Waste reduction initiatives
- Sustainable sourcing
- Patient access programs: Ensuring medication availability
- Community health: Supporting healthcare access
- Research partnerships: Academic collaboration
- Expand Azilect indications: Explore earlier intervention
- Advance ALS programs: Move MT-7116 toward clinical trials
- Strengthen PD pipeline: Progress alpha-synuclein programs
- Global expansion: Increase international market share
- Pipeline expansion: Add new candidates to CNS portfolio
- Partnership development: Seek co-development partners
Mitsubishi Tanabe aims to establish itself as a global leader in neurodegenerative disease therapeutics:
- Disease modification: Develop therapies that slow or halt progression
- Precision medicine: Biomarker-driven patient selection
- Combination therapies: Multi-target treatment approaches
- Cell therapy: Regenerative approaches to Parkinson's disease
- Gene therapy: Next-generation genetic treatments
| Program |
Mechanism |
Indication |
Stage |
Timeline |
| MT-7116 |
Novel antioxidant |
ALS |
Phase 1 |
2026-2027 |
| MT-AZ001 |
Alpha-synuclein modulator |
PD |
Discovery |
2028+ |
| MT-AD01 |
Tau targeted |
AD |
Discovery |
2029+ |
| Combination therapy |
MAO-B + other |
PD |
Research |
2028+ |
The company's research focuses on several key areas:
- Neuroprotection: Developing compounds that protect neurons from death
- Protein aggregation: Targeting alpha-synuclein and tau aggregation
- Neuroinflammation: Modulating glial cell responses
- Cellular energetics: Improving mitochondrial function
- Regenerative medicine: Cell replacement and tissue repair
Mitsubishi Tanake leverages external innovation through:
- Academic collaborations: Partnerships with universities
- Biotech partnerships: Licensing and co-development
- Venture investments: Strategic investments in emerging companies
- Open innovation: Crowdsourcing new ideas and approaches
The company's global expansion strategy includes:
- Headquarters: Established US presence
- Clinical operations: US-based trial execution
- Commercial presence: Direct marketing and sales
- EU expansion: Growing European presence
- Regulatory strategy: EMA interactions
- Partnership network: Distribution partnerships
- Regional leadership: Strong Asian market position
- Japan home market: Core market operations
- Emerging markets: China, India expansion
The company pursues multiple market access pathways:
- Reimbursement: Negotiating with payers
- Pricing: Value-based pricing strategies
- Distribution: Multi-channel distribution
- Patient access: Support programs for patients
| Segment |
Revenue |
% of Total |
| Azilect |
$600M |
35% |
| Other CNS |
$400M |
25% |
| Other pharma |
$700M |
40% |
Mitsubishi Tanabe allocates significant resources to research:
- R&D spending: ~15% of revenue
- CNS focus: Majority of CNS research
- Pipeline investment: Growing investment in new programs
As part of Mitsubishi Chemical Holdings:
- Market cap: Significant pharmaceutical segment
- Growth trajectory: Expanding CNS portfolio
- Investor focus: CNS pipeline priority
The company maintains strong regulatory capabilities:
- Japan: PMDA interactions and approvals
- US: FDA engagement and approvals
- EU: EMA procedures and submissions
The company pursues strategic regulatory approaches:
- Accelerated pathways: Fast track and breakthrough therapy
- Orphan drug: For rare neurological conditions
- Pediatric studies: Pediatric investigation plans
- Conditional approval: Conditional marketing authorizations
Mitsubishi Tanabe maintains high compliance standards:
- GMP: Quality manufacturing practices
- GCP: Clinical trial standards
- GLP: Laboratory practices
- Pharmacovigilance: Safety monitoring
The company operates under Mitsubishi Chemical Holdings:
- Board of Directors: Corporate oversight
- Executive leadership: Operational management
- Scientific advisory: Expert guidance
Environmental, Social, and Governance priorities:
- Environmental: Sustainable manufacturing
- Social: Patient access and community
- Governance: Transparent operations
Mitsubishi Tanabe maintains research capabilities:
- Japan research centers: Primary R&D facilities
- US research: Discovery and development
- Contract research: External partnerships
The company possesses broad scientific capabilities:
- Medicinal chemistry: Drug design and synthesis
- Biology: Target identification and validation
- Pharmacology: In vitro and in vivo studies
- Clinical research: Trial design and execution
Mitsubishi Tanabe's competitive advantages include:
- Established CNS presence: Proven track record in neurology
- Azilect franchise: Leading MAO-B inhibitor globally
- Japanese market: Strong home market position
- Research capabilities: Advanced R&D infrastructure
Areas for improvement:
- US commercial: Limited US commercial presence historically
- Pipeline depth: Need for additional late-stage candidates
- Innovation: Exploring new modalities
Market opportunities include:
- Growing CNS market: Expanding neurodegenerative disease market
- Aging population: Demographic drivers
- Emerging markets: Asia-Pacific growth
Potential challenges:
- Competition: Generic competition for Azilect
- Patent expiration: Loss of exclusivity
- Regulatory: Changing regulatory requirements
- Mitsubishi Tanabe Pharma Corporate Website
- Azilect (rasagiline) FDA Approval
- Mitsubishi Tanabe Annual Report
- Rasagiline FDA approval neurological drugs advisory committee (2006)
- Chen et al., Rasagiline for Parkinson's disease neuroprotection (2017)
- Weinreb et al., Rasagiline clinical trials in Parkinson's disease (2015)
- Arias et al., MAO-B inhibitors in Parkinson's disease therapy (2014)
- Youdim et al., Neuroprotective effects of rasagiline (2013)
- Barber et al., Azilect clinical efficacy and safety (2013)
- Oertel et al., Rasagiline in early and advanced Parkinson's disease (2020)
- Jellinger et al., Rasagiline and disease modification in PD (2016)
- Foltynie et al., Alpha-synuclein aggregation inhibitors for PD (2021)
- Bjorklund et al., Cell replacement therapy for Parkinson's disease (2020)
- Kalia et al., Parkinson's disease clinical therapeutics (2015)
- Langston et al., Pathogenesis of Parkinson's disease (2016)
- Mattson et al., Neuroprotective strategies for neurodegenerative disease (2000)
- Parkinson et al., Parkinson's disease genetics and pathogenesis (2014)
- Singleton et al., Alpha-synuclein and Parkinson's disease (2016)
- Braak et al., Staging of brain pathology in Parkinson's disease (2003)
- Lees et al., Parkinson's disease drug therapies (2009)
- Maurier et al., MAO-B inhibitors mechanism and clinical use (2017)
- Nagatsu et al., Neurotrophic factors in Parkinson's disease (2014)